Information about Remdesivir

Wiki source

Preliminary data from an international multi-center, placebo controlled double-blind randomized controlled trial carried out by the US National Institutes of Health suggests that remdesivir is effective in reducing the recovery time from 15 to 11 days in people hospitalized with COVID‑19. On 29 April 2020, based on results of the ACTT trial, the National Institute of Allergy and Infectious Diseases (NIAID) announced that remdesivir was better than a placebo in reducing time to recovery for people hospitalized with advanced COVID‑19 and lung involvement. The study appeared on The New England Journal of Medicine website almost a month later on 22 May 2020 and, despite generally positive results, the study concluded that "given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient. " A previous Chinese study published in The Lancet did not show significant benefits or drawbacks of using remdesivir, concluding that further research is required to understand the effectiveness of the drug. John David Norrie of the Clinical Trials Unit of the University of Edinburgh Medical School criticised that article as underpowered due to a lack of significant results as well as the fact that the study was ended prematurely. Based on the results of its study, the NIH stopped the ACTT trial and provided remdesivir to participants assigned to received placebo.